Natco Pharma

Indian pharmaceutical company

Natco Pharma
Company typePublic
Traded as
NSE: NATCOPHARM
BSE: 524816
IndustryPharmaceuticals
Founded1981
FounderVC Nannapaneni
Headquarters
Hyderabad, Telangana
,
India
Area served
Global
Key people
VC Nannapaneni (Chairman and MD)[1]
Rajeev Nannapaneni (CEO and Vice Chairman)[2]
RevenueIncrease ₹2,811 crore (US$340 million) (FY23)[3]
Net income
Increase ₹715 crore (US$86 million) (FY23)[3]
Websitenatcopharma.co.in

Natco Pharma is an Indian multinational pharmaceutical company based in Hyderabad. The company manufactures finished dosage formulations active pharmaceutical ingredients and crop health science products.[4] It is a major producer of branded oncology medicines[5] and hepatitis C drugs.[6] The company specialises in producing complex medicines at affordable prices.[7][8] In 2019, Natco launched its crop health sciences division.[9][10]

History

  • In 2003, Natco Pharma launched Veenat, a generic version of Novartis AG's anti-cancer drug Glivec. It won the subsequent patent protection legal battle against Novartis in 2013.[11]
  • In 2012, Natco Pharma obtained compulsory license to produce a cheaper and generic version of Bayer's anti-cancer medication Nexavar.[6]
  • In the United States, it launched influenza medication Tamiflu with marketing partner Alvogen, multiple sclerosis treatment drug glatiramer acetate in partnership with Mylan, and hepatitis C drugs under a licensing agreement with Gilead Sciences.[11]
  • In 2015, Natco Pharma started production of Sofosbuvir in Nepal.[12]
  • In 2016, Natco Pharma launched the first Tamiflu capsule in the US market.[13]
  • In 2017, Natco Pharma launched a generic version of blood cancer drug Pomalidomide at a 98% discount to the drug's selling price in the United States.[14]
  • In 2019, Natco Pharma initiated work on green-field manufacturing facilities for producing niche agrichemical products in Nellore district, Andhra Pradesh.[15]

External links

  • Official website

References

  1. ^ "Facing headwinds in US, Natco Pharma looks to scale up business in China". Livemint. Retrieved 19 April 2020.
  2. ^ "Natco Pharma: In fine fettle". Forbes India. Retrieved 19 April 2020.
  3. ^ a b "Natco Pharma posts 345% sequential growth in Q4 PAT to ₹276 crore". Mint. 29 May 2023. Retrieved 27 June 2023.
  4. ^ "Our Business | Natco Pharma". Retrieved 25 April 2022.
  5. ^ "Natco Pharma lines up 20 'Para IV' products". The Hindu Business Line. Retrieved 19 April 2020.
  6. ^ a b "How Natco defied the odds to rise up India's pharma ladder". Moneycontrol. Retrieved 19 April 2020.
  7. ^ PTI (17 December 2020). "Natco Pharma launches anti blood clot medication, Rivaroxaban, in India". The Economic Times. Retrieved 25 April 2022.
  8. ^ Akolkar, Shrikant (9 March 2017). "Natco Pharma: Top league player" (PDF). Angel One. Retrieved 25 April 2022.
  9. ^ "Mission & Heritage | Natco Pharma". Retrieved 25 April 2022.
  10. ^ Sridhar, G. Naga (25 November 2020). "Natco Pharma expects agri business to be key growth lever". www.thehindubusinessline.com. Retrieved 24 April 2022.
  11. ^ a b "Niche Play". Business Today. Retrieved 19 April 2020.
  12. ^ "Natco Pharma History | Natco Pharma Information". The Economic Times. Retrieved 3 February 2022.
  13. ^ "Bayer cancer drug faces new Nexavar patent problems in India". www.thepharmaletter.com. Retrieved 3 February 2022.
  14. ^ "Natco Pharma launches blood cancer drug priced Rs 5,000–20,000, down 98% from US price". Firstpost. 10 May 2017. Retrieved 31 July 2020.
  15. ^ "Natco Pharma to invest Rs 100 cr for setting up agrichemical facilities in Andhra". 25 January 2019.
Authority control databases Edit this at Wikidata
  • ISNI